Metsera, Inc. (MTSR)

NASDAQ: MTSR · Real-Time Price · USD
33.88
+0.89 (2.70%)
Aug 1, 2025, 3:30 PM - Market open
2.70%
Market Cap3.56B
Revenue (ttm)n/a
Net Income (ttm)-307.82M
Shares Out 105.06M
EPS (ttm)-5.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,139,750
Open31.24
Previous Close32.99
Day's Range31.01 - 34.25
52-Week Range12.30 - 47.40
Betan/a
AnalystsStrong Buy
Price Target55.25 (+63.08%)
Earnings DateJul 28, 2025

About DESP

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2025
Employees 81
Stock Exchange NASDAQ
Ticker Symbol MTSR
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for MTSR stock is "Strong Buy." The 12-month stock price target is $55.25, which is an increase of 63.08% from the latest price.

Price Target
$55.25
(63.08% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025

3 days ago - GlobeNewsWire

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obes...

7 weeks ago - GlobeNewsWire

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability wi...

7 weeks ago - Benzinga

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a mo...

7 weeks ago - Reuters

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and  potential first-in-category monthly GLP-1 + Amylin combination Well-...

7 weeks ago - GlobeNewsWire

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations

2 months ago - GlobeNewsWire

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025

2 months ago - GlobeNewsWire

Metsera to Present at Bank of America 2025 Global Healthcare Conference

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesi...

3 months ago - GlobeNewsWire

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025

4 months ago - GlobeNewsWire

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obes...

5 months ago - GlobeNewsWire

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing and a strong safety profile. Positive phase 2a results for MET-097i showed signific...

5 months ago - Seeking Alpha

Why this newly public biotech could become a force in obesity treatments

Metsera's GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.

5 months ago - Market Watch

This weight-loss drug stock could deliver a 90% return in 2025

Metsera Inc (NASDAQ: MTSR) has been pushing to the upside since its debut on Nasdaq on January 31st. But analysts are convinced the recent price action is a drop in the bucket compared to where this s...

5 months ago - Invezz

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...

6 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...

6 months ago - Seeking Alpha

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.

6 months ago - Reuters

Weight-loss drug developer Metsera raises $275 million in US IPO

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company s...

6 months ago - Reuters

Metsera Announces Pricing of Initial Public Offering

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...

6 months ago - GlobeNewsWire

Metsera Readies $275 Million IPO For Obesity Treatments

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and related conditions. The firm's lead candidate, MET-097i, is in Phase 2b trials, w...

6 months ago - Seeking Alpha

Weight-loss drug developer Metsera reveals wider loss in US IPO filing

Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S. initial public offering on Friday.

7 months ago - Reuters

Metsera IPO Registration Document (S-1)

Metsera has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC